Table 1. The baseline characteristics of enrolled patients and tumor response 8 weeks after apatinib treatment.
| No. | Gender | Age | Pathology | TNM stage | Metastasis site | VEGF | Accumulated RAI dose (mCi) | RAI* uptake | Response |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 44 | PTC | pT3N1bM1 | Pulmonary & head | - | 300 | No | PR |
| 2 | M | 47 | PTC | pTxN1aM1 | Pulmonary & bone | - | 305 | No | PR |
| 3 | M | 76 | PTC | pT4aN1bM1 | Pulmonary | + | 300 | No | PR |
| 4 | F | 32 | PTC | pT4aN0M1 | Pulmonary | - | 200 | No | SD |
| 5 | M | 51 | Poorly-PTC | pT4aNxM1 | Pulmonary | + | 350 | No | PR |
| 6 | F | 75 | PTC | pT4aN1bM1 | Pulmonary & bone | - | 230 | No | PR |
| 7 | M | 65 | PTC | pT4aN1bM1 | Pulmonary | N/A | 350 | No | PR |
| 8 | F | 46 | PTC | pT3N1bM1 | Pulmonary & bone | - | 630 | No | PR |
| 9 | F | 63 | PTC | pT4aN1bM1 | Pulmonary | + | 325 | Yes | PR |
| 10 | F | 49 | PTC | pT4aN1bM1 | Pulmonary | - | 440 | No | PR |
VEGF: vascular endothelial growth factor; RAI: radioactive iodine; PTC: papillary thyroid cancer; PR: partial response;
SD: stable disease;.
N/A: not available.
*RAI uptake in metastasis lesions at the first RAI therapy.